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Abstract. It is well understood that patients with different diseases may have a variety of specific proteins (e.g., type,
amount, and configuration) in their plasmas. When nanoparticles (NPs) are exposed to these plasmas, the resulting
coronas may incorporate some of the disease-specific proteins. Using gold (Au) NPs with different surface properties
and corona composition, we have developed a technology for the discrimination and detection of two neurodegenerative
diseases, Alzheimer’s disease (AD) and multiple sclerosis (MS). Applying a variety of techniques, including UV-visible
spectra, colorimetric response analyses and liquid chromatography-tandem mass spectrometry, we found the corona-NP
complexes, obtained from different human serums, had distinct protein composition, including some specific proteins that are
known as AD and MS biomarkers. The colorimetric responses, analyzed by chemometrics and statistical methods, demonstrate
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promising capabilities of the technology to unambiguously identify and discriminate AD and MS. The developed colorimetric
technology might enable a simple, inexpensive and rapid detection/discrimination of neurodegenerative diseases.
Keywords: Alzheimer’s disease, colorimetric technology, disease-specific protein corona, gold nanoparticles, multiple
sclerosis
INTRODUCTION
Exposure of nanoparticles (NPs) to physiological
fluids results in their surfaces being covered by a
biomolecular layer described as a “protein corona”
[1–4]. The corona layer gives NPs a different iden-
tity compared to their original surface characteristics
that will interact with biological systems in a spe-
cific way. The composition of the corona defines
the bio-distribution, circulation half-life, toxicity and
therapeutic efficacy of NPs [5–8]. Therefore, deep
understanding of the protein corona composition is
crucial to the predict the outcome of NPs in vivo [9].
Slight variations in the corona composition and
structure can induce substantial differences in the
biological fate of NPs [7, 10]. For instance, incorpora-
tion of apolipoprotein E into the corona composition
can enable NPs to cross the blood-brain barrier
(BBB) and reach brain tissue [11]. Recently, our
group and others have demonstrated that changes
in plasma composition, mediated by the type of
disease, may be detected in the protein corona of
exposed NPs [12–14]. This suggests patients with
specific types of diseases have distinct corona com-
position termed “disease-specific protein corona”
(DSPC) [12]. It has been proposed that the formation
of the DSPC for different diseases is a consequence
of the conformation, concentration, and function
of the types of proteins in human plasma/serum.
For example, patients with Alzheimer’s disease
(AD) experience higher levels of the serum amyloid
protein, clusterin, Alpha-1-antichymotrypsin, com-
plement factor H and -1/-2-microglobulin with
less Apo C3, transthyretin, A42:A40 ratios and
complement C4 compared to normal cases [15–20].
As another example, changing concentrations of
anti-myelin antibodies, Epstein-Barr virus, inter-
feron -neutralizing antibodies, and tumor necrosis
factor-related apoptosis-inducing ligand are serum
biomarkers in multiple sclerosis (MS) patients
[21–23]. In addition, the proteins involved in blood
clotting, influence lipid transport pathways leading
to a change in the composition of the serum of
MS patients, especially in the early stages the dis-
ease [24]. These disease-specific serum changes can
be used as potential biomarkers at the early stages,
before appearance of any physical characteristic sign
for MS disease. The A oligomer species (AOs) are
known as biomarkers that appear in initial phases of
AD [25].
Small variations in the composition of plasma can
makesignificantchangesinthecoronacompositionon
the surfaces of the same NPs [26]. One could expect,
therefore, that the DSPC may be used as a tool to
discriminate and/or detect different types of diseases
by investigating the plasma of patients with particular
diseases. The development of diagnostic approaches
for the identification and discrimination of diseases
is one of the major challenges facing the scientific
community. A major obstacle in disease detection
is the clinical symptoms of some diseases, such as
fibrillation-related disorders, cancer and MS, only
appear at the late stages [27–30]. Currently, a patient’s
serum and cerebrospinal fluid (CSF) are used to
discover new biomarkers (e.g., proteins, metabolites,
and macromolecules). Disease-specific biomarkers
(e.g., proteins and metabolites) are mainly identified
using liquid chromatography-tandem mass spec-
trometry (LC-MS/MS). Madasamy’s group identified
several AD biomarkers using flow cytometer-
based approaches [31–38]. The analysis of whole
proteome and metabolome profiles of patient’s
serum/cerebrospinal fluid are, however, invasive,
time consuming and expensive. In addition, analyt-
ical technics used for these analyses have moderate
sensitivity.
Among the various type of sensors, the colorimetric
technology is recognized as a rapid, economical, and
concise approach for the detection of a wide range of
compounds (e.g., biomolecules, environmental pollu-
tion compounds like NPs, toxic gases, heavy metals,
and toxic industrial chemicals) [39–42]. Array-based
detection works on the basis of cross-reactive interac-
tions of different dyes with an analyte leading to the
formation of specific colorimetric patterns. Although
there is no specific interaction between a dye and
analyte, the cross-reactive interactions of dye with
sensor elements can provide a unique pattern for the
desired analyte [43]. This approach is mimicked from
the human mammalian olfactory system for the sense
of smell [44]. In this paper, we describe the design
and application of a colorimetric technology for the
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detection and discrimination of AD and MS. The
system consists of four elements of spherical gold
(Au) NPs of the same size but with different sur-
face coatings including citrate, cysteine, cysteamine,
and polyethyleneglycole. The Au NPs were incu-
bated with 10% and 100% serums obtained from
patients with different diseases. The system responses
were measured by UV-visible spectra and analyzed by
hierarchical cluster analysis (HCA), principal compo-
nent analysis (PCA), andcolorimetricdifferentprofile
(CDP). Variation in the composition of the protein
corona at the surfaces of Au NPs can change their
surface plasmon resonance (SPR), which is the basis
of sensing in the proposed technique. We have also
probed the composition of the protein corona at the
surfaces of various NPs obtained from the plasma
of patients with different diseases using LC-MS/MS.
Serum proteins have low binding affinity to NPs func-
tionalized with zwitterions (Cystein) and therefore
lower numbers of proteins, compared to other NPs,
can be adsorbed to the surface of these NPs [45]. In
this study, we identified the proteins present in the
hardcoronaofcitrate/cyteamine/polyethyleneglycole
functionalized NPs.
MATERIALS AND METHODS
Materials
L-Cysteamine, sodium citrate, cysteine, thio-
sulfate sodium, sodium carbonate, glycine, Tris
(hydroxymethyl) aminomethane, ammonium persul-
fate, hydrochloric acid, Sodium chloride, sodium
hydrogen phosphate, potassium dihydrogen phos-
phate and Sodium hydroxide were purchased from
Merck. Sodium borohydride, acetic acid, silver
nitrate, methanol, ethanol, formaldehyde, sodium
dodecyl sulfate, Tetramethylethylenediamine, 2-
mercaptoethanol, glycerol, polyethylene glycol,
hydrogen tetrachloroaura cetyltrime-thylammonium
bromide, L-ascorbic acid and other materials were
purchased from Sigma.
Au NPs synthesis and functionalization with
citrate, cysteine, cysteamine and polyethylene
glycol
Citrate-stabilized Au NPs were prepared using
Turkevich method with slight modification [46]. In
order to prepare citrate-coated Au NPs, 5 ml of
sodium citrate (38.8 mmol L–1) was added to boil-
ing solution of 50 ml of HAuCl4 (1.0 mmol L–1) and
stirred for 30 min at 100◦C. In the next step, the
synthesized Au NPs were cooled and functionalized
with cysteine, cysteamine or polyethylene glycol.
To this end, Au NPs were treated with each of
cysteine (8M), cysteamine (2M) and thiolated
polyethylene glycol (10M) at room temperature,
for 10 hours at pH 7.4. After 10 h of incubation, the
produced cysteine-Au, cysteamine-Au and thiolated
polyethylene glycol-Au were collected and purified
by triplicate centrifugation (at 13000 g for 10 min)
and washing.
Characterization of synthesized Au NPs
The synthesized Au NPs were characterized using
UV-Visible spectrophotometer and transmission
electron microscopy (TEM). All absorbance analyses
were accomplished using a Lambda (PerkinElmer,
USA) spectrophotometer at room temperature. The
Au NP size and morphology were figure out by
Phillips CM200 transmission electron microscope
(TEM) equipped with an AMT 2 2 CCD camera at
an accelerating voltage of 200 kV.
Serum preparation
Blood samples were collected from all volunteers
after signing informed consent. The blood samples
collected in clot tubes were allowed to clot at 4◦C for
30–60 minute and centrifuged following clot forma-
tion at 2500 g for 10 min at 4◦C. The serum fractions
obtained from same subjects (Patients with same dis-
ease) were pooled, divided into aliquots and frozen at
–20◦C. It should be noted that the sex and age (70–80)
matched volunteers were selected for this study.
Preparation of corona-coated
citrate/cysteine/cysteamine/polyethylene
glycol-Au NP complexes
As slight temperature change affects the protein
corona formation, the serums (10% and 100%) from
AD, MS and normal cases and functionalized Au
NPs were maintained at 37◦C for 10 min [47]. In
the next step, the functionalized Au NPs were incu-
bated with the serums (10% and 100%) at a final
concentration of 100g ml–1 at 37◦C for 60 min
(Total volume was 500l). Immediately after 60 min,
the solutions were centrifuged for 20 min at 14000 g
at 15◦C to separate the corona-coated NP com-
plexes. Then, the supernatant was gently removed
and NP-protein pellet was resuspended in PBS (15◦C)
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and centrifuged for 15 min at 14000 g at 15◦C. The
washing step was repeated for three times. The trip-
licate washing lead to detachment of loosely bound
proteins. Finally, the resulted hard corona-coated Au
NPs were resuspended in 250l of PBS (1%) and
used for further analyses.
Dynamic light scattering (DLS) and zeta
potential
Size distribution of corona-coated citrate/cysteine/
cysteamine/polyethylene glycol-Au complexes were
measured using Malvern PCS-4700 instrument
equipped with a 256-channel correlator. The sur-
face charges of these complexes were measured by
Malvern Zetasizer 3000 HSA. All of these analyses
were performed at 25◦C and repeated for three times.
Identiﬁcation of proteins involved in corona
using LC-MS/MS analysis
To investigate the effects of changes of serum com-
position, caused by different types of diseases, on
the composition of hard corona, the functionalized
Au NPs were incubated with 10% and 100% serums
of AD, MS, and healthy individuals. After remov-
ing the excess serum and weakly bounded proteins,
so called “soft corona”, the obtained hard corona-
Au NP complexes were evaluated using LC-MS/MS
analyses. The identity and intensity of the hard corona
proteins were determined by LC-MS/MS analysis
[Tables 2–7 (see also Supplementary Material: Equa-
tion 1 and Supplementary Table 2–7)]. Detailed on
the LC-MS/MS procedure is provided in our previous
report [48].
Fig. 1. UV-vis spectra of Au NPs functionalized with citrate, cysteine, cysteamine and polyethyleneglycole (A). Transmission electron
microscope (TEM) image of prepared Au NPs (B). Energy dispersive spectroscopy (EDS) analysis of prepared Au NPs (C).
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RESULTS AND DISCUSSION
NP synthesis and characterization
The presence of a specific peak at 520 nm con-
firmed the presence of stable Au NPs in the prepared
solutions (Fig. 1A). The UV-visible spectra of cit-
rate/cysteine/cysteamine/polyethylene glycol-coated
Au NPs demonstrated no considerable shift in the
SPR peak position. On the basis of this result, it
is evident the Au NPs have not aggregated in the
prepared solutions. Owing to their monodispersed
state, the NPs are promising candidates for inves-
tigating changes in SPR caused by disease-specific
protein coronas (DSPC). Images from transmission
electron microscopy (TEM) show sphere-shaped Au
NPs (20 nm) with a narrow size distribution (Fig. 1B).
Energy dispersive X-ray spectroscopy (EDS) analy-
sis confirmed the presence of pure Au NPs in solution
(Fig. 1C).
UV-visible spectra of DSPC-Au NP complexes
from different patients
The citrate/cysteine/cysteamine/polyethylene gly-
col-coated Au NPs were incubated with 10% and
100% serums from various patients and the final
DSPC-Au NP complexes measured by UV-visible
spectrometry at a wavelength of 400–780 nm.
Although the SPRs of all corona-coated Au NP
complexes obtained from 10% serums showed no
significant shift in peak position, the SPR intensities
of some complexes were different from each other
(Fig. 2A-D). For example, all corona-coated Au
NPs complexes obtained from serums of healthy
individuals showed the least SPR intensity except
for corona-coated citrate-NPs, which showed the
highest intensity (Fig. 2A-D). The SPR intensities
of complexes obtained from serums of AD and
MS patients were similar (Figs. 2B,D). However,
the DSPC-Au NP complexes obtained from 10%
Fig. 2. UV-vis spectra of corona-coated citrate-Au NPs (A), corona-coated cysteamine-Au NPs (B), corona-coated polyethyleneglycole-
Au NPs (C) and corona-coated cysteine-Au NPs (D) obtained following incubation with 10% serums of normal, AD and MS cases.
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serums can be used to discriminate between healthy
individuals and AD/MS patients. It should be noted
that these complexes do not discriminate between
different diseases. For DSPC-NP complexes from
100% serums, changes in SPR intensity, and in some
cases, peak broadening, were observed (Fig. 3A-D).
According to the spectral responses recorded for
corona-coated citrate-Au NP complexes, distinctive
spectra are characteristic for AD and MS (Fig. 3A).
As a result of DSPC formation, distinct spectral
response permits the facile and rapid detection and
discrimination of AD and MS. The different spectral
patterns suggest the coronas have a different protein
composition.
Analysis of the array responses by hierarchical
cluster analysis, principal component analysis
and color difference proﬁle
In the method of HCA, different diseases are clus-
tered on the basis of their spatial distances and the
results plotted on a dendrogram. The HCA dendro-
gram represents a view of data clustering in which the
cluster distance is known as an index of likeness level
of samples [49]. For 10% serum, the HCA dendro-
gram shows AD and MS have short or insignificant
cluster distances while both diseases have long clus-
ter distances to healthy individuals (Fig. 4A). On the
basis of the HCA dendrogram for 100% serum, all AD
and MS patients and healthy individuals have long
cluster distances from each other (Fig. 4B). The array
responses were also analyzed using principal compo-
nent analysis (PCA) to quantitatively evaluate sample
dispersion and determine similarity in the diseases. In
the PCA plot, the level of class distribution and sepa-
ration is known as index of similarity level [50]. In the
score plots generated for 10% serum, the horizontal
PC1 axis and the vertical PC2 axis captured 96.1%
and 3.2% of the variance, respectively (Fig. 5A).
As shown in Fig. 5A, the healthy samples can just
be discriminated from the disease cases. Indeed, the
degree of class separation among different diseases
were insignificant, and hence, they cannot be discrim-
inated from each other. In the score plot designed for
100% serum, the horizontal PC1 axis and the vertical
PC2 axis captured 93.2% and 5.4% of the variance,
Fig. 3. UV-vis spectra of corona-coated citrate-Au NPs (A), corona-coated cysteamine-Au NPs (B), corona-coated polyethyleneglycole-Au
NPs (C) and corona-coated cysteine-Au NPs (D) obtained following incubation with 100% serums of normal, AD and MS cases.
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Fig. 4. HCA dendrogram showing the Euclidean distance among different clusters for corona profiles of 10% serum (A) and 100%
serum (B).
respectively (Fig. 5B). For 100% serum, all cases can
be discriminated from each other. The degree of class
separation among AD, MS and healthy individuals
were significant, and hence, they can be differenti-
ated (Fig. 5B). These findings can be explained by
disease-specific changes in the serum mediated by the
disease. Because the colorimetric technology devel-
oped in this study differentiate diseases on the basis
of the spectral variations driven by DSPCs, they can
specifically discriminate patients who have specific
protein coronas. In order to differentiate various dis-
eases, even at a glance, CDP was generated by taking
the value of the A of three selected visible wave-
lengths (i.e., 520, 570 and 630 nm). CDP provided
clear color changes that can be distinguished at a
glance. On the basis of the CDP for 10% serum, it
is possible to differentiate the healthy case from dis-
ease (Fig. 6A). The color changes detected for normal
cases may be related to their different SPR intensi-
ties. According to the CDP for 100% serum, all cases
(AD, MS and healthy) can be distinguished from each
other (Fig. 6B). The analysis of the collective array
responses by HCA, PCA and CDP suggest DSPC
formation can be used to develop colorimetric sen-
sor arrays that specifically discriminate and detect
different diseases.
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Fig. 5. Two-dimensional score plot showing degree of class separation among normal, AD and MS cases for 10% serum (A) and 100%
serum (B).
Size and charge of corona-coated NP complexes
Considering that the size and surface charge of
corona-coated NPs are contingent upon the type and
affinity of the adsorbed proteins [12], the same NPs
will have different properties after exposure to the
serum of different patients. Analysis of the size distri-
bution and zeta potential value of corona-coated Au
NPs obtained from serums of various patients con-
firmed this behavior (Tables 1A-D). These results
are consistent with previous studies showing per-
sonalized protein corona from various patients have
distinct size and surface charge [12, 26].
Effects of serum composition on protein corona
formation in patients with different diseases
The identified proteins were classified based on
their association within different coronas. We found
that many proteins (conserved proteins) associated
within all coronas (Supplementary Tables 1–6), while
some specific proteins exclusively appeared and/or
disappeared in hard coronas obtained from partic-
ular type of serums (Tables 2–7). In addition, the
majority of conserved proteins differently associated
within various coronas. These results suggest coronas
formed on the surfaces of NPs exposed to serum of
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Fig. 6. Color difference profile for normal, AD and MS cases for
10% serum (A) and 100% serum (B).
patients with various diseases are different in terms of
the composition and concentration (Tables 2–7, Sup-
plementary Tables 1–6). The conserved proteins (e.g.,
serum albumin, immunoglobulin, apolipoproteins,
and complement factors) showed more association
within the protein corona compared to specific pro-
teins (Supplementary Tables 1–6). For citrate-coated
NPs, the coronas obtained from 10% serums (diluted
in PBS) showed more similarity in their protein pat-
tern compared to those obtained from 100% serums
(Supplementary Table 1A,B). Similar results were
also observed for PEG-coated NPs (Supplemen-
tary Table 3A,B). Interestingly, some proteins were
specifically detected in the coronas of both AD and
MS. These proteins may help to distinguish patients
from normal cases. In the case of cysteamine-coated
NPs, apolipoproteins and platelet basic protein seem
to be the main component of the hard coronas of both
AD and MS (Supplementary Table 2A,B).
Specific proteins identified in the coronas obtained
from the serum of patients with a particular dis-
ease can be considered as biomarkers predicting
disease prevalence and risk (Tables 2–7). Inter-
estingly, some serum proteins that are known
as AD and/or MS biomarkers were specifically
detected in hard coronas obtained from serums of
AD and/or MS diseases. For example, Insulin-like
growth factor-binding protein 3, gelsolin, antithrom-
bin, clusterin, Thrombospondin-1 and platelet-basic,
which are known as MS biomarkers [51–53], were
detected in hard coronas obtained from serums of
patients with MS diseases. In addition, AD-specific
biomarkers such as Serum amyloid P, complement
factor H, Alpha-2-macroglobulin, transthyretin, clus-
terin, tau-tubulin kinase, Alpha-1-antichymotrypsin,
Apolipoprotein B100 and gelsolin were identified
in coronas obtained from serums of AD patients
[48, 54–57].
Insulin-like growth factor-binding protein 3, gel-
solin, antithrombin and clusterin, as MS biomarkers,
were only recognized in the corona of cysteamine-
NP obtained from 10% serum of MS patients
(Table 5). The MS-specific biomarkers such as
Thrombospondin-1 and platelet-basic protein were
identified in the corona of citrate-NPs obtained from
100% serum of MS patients (Table 2). Serum amy-
loid P and complement factor H, as AD biomarkers,
were recognized in the corona of cysteamine-
NPs obtained after incubation with 100% serum
of AD patients (Table 4). Alpha-2-macroglobulin,
transthyretin, clusterin, and tau-tubulin kinase, as
AD biomarkers, were only detected in the corona
of citrate-NPs obtained from 10% serum of patients
with AD (Table 3). Apolipoprotein B100 and gel-
solin, as AD biomarkers, were specifically identified
in the coronas of PEG-NPs obtained from 100% and
10% serums of AD patients respectively (Tables 6 and
7). Alpha-1-antichymotrypsin, as AD biomarker, was
only identified in the corona of citrate-NPs obtained
from 100% serum of AD patients (Table 2). This
hard corona complex also had the least amount of
apolipoprotein E compared to those obtained from
other serums. These results are in agreement with pre-
vious studies showing a decrease in the concentration
of serum apolipoprotein E in patients with AD [58].
The results of this study are in line with other
studies showing that each patient may have a disease-
specific protein corona [59, 60]. Every change in
serum protein concentration and structure may affect
the affinity of proteins toward the NPs and protein
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Table 1
DLS and zeta potential values of corona-coated citrate-Au NPs (A), corona-coated cysteamine-Au NPs (B),
corona-coated polyethyleneglycole-Au NPs (C) and corona-coated cysteine-Au NPs (D) obtained from 10%
and 100% serums of normal, AD and MS cases
A
Protein corona-coated citrate-Au DLS serum Zeta serum DLS serum Zeta serum
NPs obtained from normal/patient 10% (nm) 10% (mV) 100% (nm) 100% (mV)
Normal 53 ± 09 –9 41 ± 07 –9
Alzheimer’s disease 67 ± 05 –9 83 ± 22 –11
Multi sclerosis 51 ± 04 –8 59 ± 10 –6
B
Protein corona-coated cysteamine- DLS serum Zeta serum DLS serum Zeta serum
Au NPs obtained from normal/patient 10% (nm) 10% (mV) 100% (nm) 100% (mV)
Normal 37 ± 09 –9 65 ± 11 –10
Alzheimer’s disease 62 ± 07 –8 43 ± 10 –7
Multi sclerosis 59 ± 05 –4 85 ± 08 –6
C
Protein corona-coated PEG-Au DLS serum Zeta serum DLS serum Zeta serum
NPs obtained from normal/patient 10% (nm) 10% (mV) 100% (nm) 100% (mV)
Normal 88 ± 15 –8 127 ± 24 –8
Alzheimer’s disease 56 ± 04 –3 164 ± 21 –5
Multi sclerosis 81 ± 08 –7 68 ± 15 –6
D
Protein corona-coated cysteine- DLS serum Zeta serum DLS serum Zeta serum
Au NPs obtained from normal/patient 10% (nm) 10% (mV) 100% (nm) 100% (mV)
Normal 59 ± 13 –3 77 ± 14 –6
Alzheimer’s disease 47 ± 10 –5 60 ± 12 –4
Multi sclerosis 69 ± 16 –7 87 ± 08 –10
Table 2
Proteins only detected in the coronas of citrate-NPs obtained from 100% serums of AD and MS patients
Protein identity NSpC Protein identity NSpC
(Corona coated Citrate-NPs obtained after (Corona coated Citrate-NPs obtained after
incubation with 100% serum of AD cases) incubation with 100% serum of MS cases)
Apolipoprotein B-100 0.961888 Ketohexokinase 0.632403
Protein APOC4-APOC2 2.603969 Histone-lysine N-methyltransferase 0.061802
Ig heavy chain V-I region 5 2.04232 Disintegrin and metalloproteinase domain- 0.206624
containing protein 12
Protein SAA2-SAA4 2.235544 ATP-binding cassette sub-family C member 11 0.133295
Alpha-1-antichymotrypsin 0.547795 Complement C1q subcomponent subunit C 0.798011
Trinucleotide repeat-containing gene 6B protein 0.134548 Sickle tail protein homolog 0.096056
Tetratricopeptide repeat protein 6 0.1206 Thrombospondin-1 0.158966
Exonuclease 3’-5’ domain-containing protein 2 0.371033 Ig heavy chain V-III region POM 1.587822
Ras-related protein Rab-28 1.050776 Protein IGKV1-33 1.736743
Mitogen-activated protein kinase kinase kinase 4 0.143672 Myosin-9 0.090791
Supervillin 0.105361 Complement factor H 0.147868
RING finger protein 225 0.750325 Ig kappa chain V-II region RPMI 6410 1.398541
Nuclear pore complex protein Nup205 0.114527 Ig mu chain C region 2.817381
G-rich sequence factor 1 0.491337 Ig kappa chain V-IV region Len 1.627166
Aryl hydrocarbon receptor repressor 0.342271 Ig heavy chain V-III region BRO 1.555028
Immunoglobulin lambda-like polypeptide 5 1.776829
Apolipoprotein A-IV 1.359086
Alpha-1-acid glycoprotein 1 0.874765
Antithrombin-III 0.390998
Ig lambda chain V-IV region Hil 1.785783
Immunoglobulin J chain 1.136416
Ig kappa chain V-III region SIE 1.746631
Hemoglobin subunit beta 2.571223
Platelet basic protein 2.960657
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Table 3
Proteins only detected in the coronas of citrate-NPs obtained from 10% serums of AD and MS patients
Protein identity NSpC Protein identity NSpC
(Corona coated Citrate-NPs obtained after (Corona coated Citrate-NPs obtained after
incubation with 10% serum of AD cases) incubation with 10% serum of MS cases)
Clusterin 0.44663 Ig kappa chain V-III region SIE 2.554525
Protein FAM65C 0.22268 Apolipoprotein A-IV 0.662574
Protein APOC4-APOC2 1.16944 Apolipoprotein B-100 0.05834
Haptoglobin 0.47746 Ig heavy chain V-III region POM 2.32226
Ig heavy chain V-I region 5 1.83441 VPS10 domain-containing receptor SorCS2 0.234726
Protein IGKV1-33 1.97979 Immunoglobulin lambda-like polypeptide 5 2.598691
Pigment epithelium-derived factor 0.50625 Apolipoprotein L1 0.684043
Alpha-2,8-sialyltransferase 8F 0.52293
Integrator complex subunit 11 0.34651
Transthyretin 1.1638
Metaxin 1, isoform CRA b 0.45558
Tau-tubulin kinase 0.12849
Piezo-type mechanosensitive ion channel component 1 1.83441
Alpha-2-macroglobulin 0.14358
Ig kappa chain V-II region 1.59426
Ig alpha-1 chain C region 0.62265
Alpha-2-HS-glycoprotein 0.59489
C4b-binding protein alpha chain 0.69954
Table 4
Proteins only detected in the coronas of cysteamine-NPs obtained from 100% serums of AD and MS patients
Protein identity NSpC Protein identity NSpC
(Corona coated cysteamine-NPs obtained after (Corona coated cysteamine-NPs obtained after
incubation with 100% serum of AD cases) incubation with 100% serum of MS cases)
Coagulation factor XII 0.5714 Protein FAM65C 1.81545
Antithrombin-III 2.94556 Elongation factor Tu, mitochondrial 3.85839
Fibronectin 0.58998 Neurogenic locus notch homolog protein 4 0.91192
Complement factor H-related protein 1 2.05769 Kalirin 0.561772
Apolipoprotein A-IV 0.85322 Phosphatidylinositol 4-kinase alpha 0.807126
Ig lambda-2 chain C regions (Fragment) 6.82738 Dual 3’,5’-cyclic-AMP and -GMP 1.824797
phosphodiesterase 11A
Ig kappa chain C region 1.48438 Niban-like protein 1 2.271855
Plasma kallikrein (Fragment) 0.50384 Dynein heavy chain 8, axonemal 0.354907
ITIH4 protein 0.37288
Serum amyloid P-component 1.52581
Partitioning defective 3 homolog B 0.29235
N-terminal EF-hand calcium-binding protein 3 1.66386
Pleckstrin homology domain-containing family O 0.83774
member 1
Paralemmin-1 0.9206
Protein Hook homolog 1 0.45761
SURP and G-patch domain-containing protein 2 0.3187
Transcription factor SOX-18 0.94727
T-complex protein 1 subunit zeta 0.66757
Lysine-specific demethylase 5A 0.19789
Prothrombin 0.55308
Thrombospondin-1 0.29939
Transient receptor potential cation channel subfamily 0.42738
V member 3
Nesprin-1 0.03831
ETS translocation variant 3 0.67955
T-cell immunoreceptor with Ig and ITIM domains 1.14179
NKG2D ligand 4 1.286
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Table 5
Proteins only detected in the coronas of cysteamine-NPs obtained from 10% serums of AD and MS patients
Protein identity NSpC Protein identity NSpC
(Corona coated cysteamine-NPs obtained after (Corona coated cysteamine-NPs obtained after
incubation with 10% serum of AD cases) incubation with 10% serum of MS cases)
Ig kappa chain V-III region WOL 7.628765 Pre-mRNA-splicing factor CWC25 homolog 0.232449
Gelsolin 0.522827 Tyrosine-protein kinase SgK223 0.077132
Ig kappa chain V-III region HAH 6.367611 Glutaredoxin domain-containing cysteine-rich 0.408032
protein 2
Coagulation factor XII 0.330468 Probable C-mannosyltransferase DPY19L3 0.13872
Proline-rich protein 11 0.558875 PWWP domain-containing protein MUM1 0.142776
Ig heavy chain V-III region BRO 1.69379 Rhodopsin kinase 0.181672
Pigment epithelium-derived factor 0.483731 Sterile alpha motif domain-containing protein 11 0.15857
F-box/LRR-repeat protein 18 0.253597 ABI gene family member 3 0.295645
p53-induced death domain-containing protein 1 0.224674 Solute carrier family 15 member 2 0.141116
Fibronectin 0.085303 Synaptopodin 0.116028
Aldehyde dehydrogenase, mitochondrial 0.39734 Ig kappa chain V-II region RPMI 6410 0.784746
Puromycin-sensitive aminopeptidase 0.21692 Cytochrome c 0.98232
Cell division cycle 5-like protein 0.242841 Protein IGLV3-27 (Fragment) 0.948706
Group XIIA secretory phospholipase A2 1.063436 Immunoglobulin J chain 0.637663
Ig kappa chain V-I region Kue 0.951681
Protein IGLV3-19 (Fragment) 0.958323
Complement C1r subcomponent 0.140932
Clusterin 0.219847
Protein TRAV34 (Fragment) 0.925858
Microtubule-associated serine/threonine-protein 1.540459
kinase 4 (Fragment)
Conserved oligomeric Golgi complex subunit 5 0.124437
Ig lambda chain V-I region WAH 0.984248
Cytoplasmic dynein 2 heavy chain 1 0.023427
Ig kappa chain V-III region B6 0.991866
Pre-mRNA-processing factor 17 0.189719
Insulin-like growth factor-binding protein 3 0.364359
Apolipoprotein L1 0.262439
Protein IGLV3-21 (Fragment) 0.927273
Ig gamma-3 chain C region 1.615353
Protein IGKV1-8 1.734001
Protein IGKV1-12 1.725268
Alpha-1-antitrypsin 1.729556
Complement factor H-related protein 1 1.226112
Alpha-2-macroglobulin 0.353378
Complement C1q subcomponent subunit B 1.295696
Serotransferrin 0.449272
Protein IGHV3OR16-12 (Fragment) 0.896426
Ig heavy chain V-I region V35 0.887186
Haptoglobin 0.510588
Alpha-2-HS-glycoprotein 1 0.585646
Antithrombin-III 0.438792
Ig heavy chain V-I region 5 (Fragment) 1.805906
Ig lambda chain V-I region BL2 0.850798
Alpha-1-acid glycoprotein 1 0.981693
Protein IGHV3-15 (Fragment) 0.892887
Ig kappa chain V-III region NG9 (Fragment) 2.151356
Ig heavy chain V-I region Mot 0.849858
replacement events on the NP surface regulated pre-
dominantly by the Vroman effect [61]. Therefore,
it is possible to detect and discriminate different
diseases based on diseases-specific protein corona
pattern. NPs may show different colloidal stabili-
ties in physiological fluids depending on the type
of protein adsorbed to the surface. For example,
proteins attached to the NP surface may decrease
the surface charge and consequently neutralize elec-
trostatic repulsion among NPs [62]. The protein
corona may also act as a connector and link NPs
to each other [63]. These types of protein coronas
may increase NP agglomeration. In contrast, some
proteins may increase the stability of NPs via increas-
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Table 6
Proteins only detected in the coronas of PEG-NPs obtained from 100% serums of AD and MS patients
Protein identity NSpC Protein identity NSpC
(Corona coated PEG-NPs obtained after (Corona coated PEG-NPs obtained after
incubation with 100% serum of AD cases) incubation with 100% serum of MS cases)
Apolipoprotein B-100 0.159293 Anoctamin-4 0.32462
Beta-2-glycoprotein 1 0.714875 Interferon regulatory factor 2-binding protein 1 0.586538
Inter-alpha-trypsin inhibitor heavy chain H2 0.257154 Olfactory receptor 52A5 1.006359
CYP11B1 protein 0.420367 Tenomodulin 0.974491
Glutamate receptor-interacting protein 1 0.223631 DCN1-like protein (Fragment) 1.540208
Insulin-like growth factor-binding protein 3 0.864359 Kelch-like protein 11 0.451446
Heat shock protein 105 kDa 0.282637 Dynein heavy chain 2, axonemal 0.071268
Pyruvate carboxylase, mitochondrial 0.211194 Cytochrome b-c1 complex subunit 1, mitochondrial 0.687286
C-C chemokine receptor type 7 0.638576
Armadillo repeat-containing X-linked protein 5 0.439123
Coiled-coil domain-containing protein 150 0.212622
Peripheral-type benzodiazepine receptor- 0.136851
associated protein 1
Ig heavy chain V-I region 5 (Fragment) 2.14205
Enhancer of filamentation 1 0.294826
Plexin-B2 (Fragment) 1.043972
Ubiquilin-4 0.428766
Table 7
Proteins only detected in the coronas of PEG-NPs obtained from 10% serums of AD and MS patients
Protein identity NSpC Protein identity NSpC
(Corona coated PEG-NPs obtained after (Corona coated PEG-NPs obtained after
incubation with 10% serum of AD cases) incubation with 10% serum of MS cases)
Ig heavy chain V-I region 5 3.734713 Ig mu chain C region 3.014587
Gelsolin 0.556997 Immunoglobulin lambda-like polypeptide 5 5.133242
N-terminal EF-hand calcium-binding protein 3 2.050352 Proline-rich protein 11 0.988207
Brefeldin A-inhibited guanine nucleotide- 0.198353 Ninein 0.162846
exchange protein 3
Serotransferrin 4.285257 Immunoglobulin J chain 2.18873
Alpha-2-HS-glycoprotein 1.211148 Structural maintenance of chromosomes protein 1B 0.275262
Fibrinogen alpha chain 0.502597 Zinc finger protein ZIC 5 2 0.578732
SEC14-like protein 5 0.501794
ing steric/entropic constancy [64]. Corona-coated Au
NP complexes obtained from the serums of patients
with different diseases have distinct protein compo-
sition and concentration. One may expect Au NPs to
show different colloidal stability and agglomeration
in different serums and thus exhibit variation in SPR
intensity/peak position.
The concentration and structure of proteins
involved in the corona play a crucial role in deter-
mining the colloidal stability of Au NPs [65, 66].
For example, minor Au NP agglomeration was
detected when NPs were incubated at high and low
concentrations of hemoglobin (Hb). In contrast, Au
NP agglomeration considerably increased when a
monolayer of Hb coated the NP surface. In this situa-
tion, Hb deactivated the electrostatic repulsion forces
and/or connected the particles as a pons [65]. Protein
unfolding can also affect NP colloidal stability. The
unfolded Albumin caused Au NP aggregation [66].
Structural integrity and protein intensity of the corona
governed colloidal stability of NPs in physiological
media.
Conclusion
Changes in serum can accurately reflect the state
and stage of disease in patients. It is, therefore, pos-
sible to detect disease type/progress on the basis of
specific changes in composition of serum. Depending
on the type and severity of disease, each patient
may have distinct DSPC containing disease-specific
biomarkers. Owing to the formation of DSPC, some
proteins only appeared or disappeared in the corona
of a particular disease and may be considered as a
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potential biomarker for indicating or predicting dis-
ease prevalence/progress or risk. The DSPC-Au NP
complexes obtained from serums of different patients
showed distinct array responses. The DSPC-based
colorimetric technology fulfills the key requirements
of sensitivity, specificity, facility, and affordability
required for rapid and efficient diagnosis of diseases.
The colorimetric technology developed in this study
are able to discriminate and detect AD and MS on the
basis of the DSPC. Further developments are, how-
ever, needed to improve the specificity and sensitivity
of DSPC-based colorimetric technology.
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